Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-05-05
Grygiel Nancy A. Files Amgen (AMGN) Form 4 - May 05, 2026
Grygiel Nancy A. traded 561 AMGN shares worth $25.0K in this Form 4 filing, reported to the SEC on 2026-05-05.
- Insider
- Grygiel Nancy A.
- Issuer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Period
- 2026-05-05
- Accession
- 0000318154-26-000076
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Grygiel Nancy A. | 2026-05-06 | Sell | 76 | $329.59 | $25.0K | Direct |
| Grygiel Nancy A. | 2026-05-05 | Buy | 485 | $0.00 | $0.00 | Direct |
| Net change | +409 | −$25.0K | ||||
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Track AMGN insider activity
Get alerted when Amgen Inc. executives buy or sell their shares.